Orakl Oncology 融资 3400 万美元，用虚拟癌症患者预测临床试验结果
Orakl Oncology Raises $34M to Predict Cancer Clinical Trial Outcomes with 90% Accuracy
这家法国公司把肿瘤类器官养在实验室里当"虚拟病人"，再用模型预测药厂临床试验成败，号称 90% 准确率。跟纯靠历史基因组数据的方法比，多了活体实验验证这层。关注 AI 制药、临床前筛选的从业者可以看看。
法国 Orakl Oncology 完成 3400 万美元 A 轮融资。公司 2023 年从 Gustave Roussy 癌症中心独立出来，核心思路是构建"虚拟癌症患者"队列来预测临床试验结果，官方称预测准确率达到 90%。
技术上，Orakl 不只依赖静态的回顾性基因组数据库训练算法，而是在湿实验室中培养肿瘤类器官，把真实实验数据与机器学习结合。肿瘤类器官保留了患者肿瘤的生物学特性，模型能在药物进入大规模临床试验前模拟其对不同患者群体的响应。
这条路数与传统生信公司不同：多数竞品用历史组学数据做回顾性预测，Orakl 用前瞻性活体实验数据训练模型，验证环节更贴近真实临床。对药企来说，这类工具可以提前砍掉成功率低的候选药物，节省临床试验动辄数亿美元的成本。
Orakl Oncology Raises $34M to Predict Cancer Clinical Trial Outcomes with 90% Accuracy
What You Should Know Virtual Cancer Patients: Merging Tumor Organoids with Clinical AI Founded in 2023 as a spin-out of the Gustave Roussy cancer campus in France, Orakl bridges wet-lab experimental biology and machine learning by constructing cohorts of virtual cancer patients. Rather than training algorithms exclusively on static, retrospective genomic databases, the company cultures ... Read More
This report is categorized under AITOP's "Industry" desk, focusing on Europe's AI governance and technology ecosystem. Key entities and technical topics under continuous tracking include Orakl Oncology, 肿瘤类器官, 临床试验, AI制药.
Source attribution: curated from HIT Consultant (@Fred Pennic).
